Skip to main content

Advertisement

Table 4 Cumulated percentage of patients reporting ≥ 3 upper respiratory tract infections and ≥ 3 acute otitis media episodes during the study period

From: A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections

Infection Month
1 (%) 2 (%) 3 (%) 4 (%) 5 (%) 6 (%)
URTI
 Group A treatment 3 months 0 5 12* 14* 18* 21*
 Group B placebo 0 7 22 31 40 52
 Group C treatment 6 months 0 6 11* 15* 16* 17*
AOM
 Group A treatment 3 months 0 2 6* 13* 19* 21*
 Group B placebo 0 4 15 24 36 44
 Group C treatment 6 months 0 3 7* 12* 16* 19*
  1. AOM: acute otitis media; URTI: upper respiratory tract infection
  2. * p < 0.05 vs placebo; no other significant differences between the groups